2,852
edits
Psychedelic Therapy Inclusion and Exclusion Criteria: Difference between revisions
Psychedelic Therapy Inclusion and Exclusion Criteria (view source)
Revision as of 01:07, 26 October 2023
, 01:07, 26 October 2023no edit summary
mNo edit summary |
|||
| Line 3: | Line 3: | ||
* People taking '''Kentanserin''' (a rare research chemical) or '''olanzapine''' (an atypical antipsychotic) as they can can [[Trip Terminator|''terminate'' a trip]]. | * People taking '''Kentanserin''' (a rare research chemical) or '''olanzapine''' (an atypical antipsychotic) as they can can [[Trip Terminator|''terminate'' a trip]]. | ||
* There is some evidence to suggest people with history of '''psychosis' ''should not take psychedelics; Quite ironically Aldous Huxley - the man who co-created the word''''' ''psychedelic''<nowiki/>', who had a brother with bipolar disorder and a history of psychosis in his family,- would be screened out of most psychedelic trials and clinics today. | * There is some evidence to suggest people with history of '''psychosis' ''should not take psychedelics; Quite ironically Aldous Huxley - the man who co-created the word''''' ''psychedelic''<nowiki/>', who had a brother with bipolar disorder and a history of psychosis in his family,- would be screened out of most psychedelic trials and clinics today. | ||
* Presence or history of '''mania''' or '''bipolar disorder.''' | * Presence or history of '''mania, personality''' or '''bipolar disorder.''' | ||
More specifically, taking the most recent clinical trials<ref>'''Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.''' '''Goodwin, G.M., Croal, M., Feifel, D. ''et al.''''' ''Neuropsychopharmacol.'' (2023). Accessed 15 Jul 2023 via <nowiki>https://www.nature.com/articles/s41386-023-01648-7</nowiki></ref> below is a composite of best practice. | More specifically, taking the most recent clinical trials<ref>'''Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.''' '''Goodwin, G.M., Croal, M., Feifel, D. ''et al.''''' ''Neuropsychopharmacol.'' (2023). Accessed 15 Jul 2023 via <nowiki>https://www.nature.com/articles/s41386-023-01648-7</nowiki></ref> below is a composite of best practice. | ||